Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.

US biotech Biohaven last week received a commitment from Oberland Capital to invest up to $600 million in the company. Also, ...

CVS Health (CVS) is one of the largest healthcare companies in the country, boasting a vertically integrated business that ...

Wall Street expects Palantir to earn $0.13 per share, representing a 62% year-over-year increase. Revenue is projected to ...

Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...